掲示板のコメントはすべて投稿者の個人的な判断を表すものであり、
当社が投資の勧誘を目的としているものではありません。
-
24(最新)
大手との提携⁈
承認前でこの動き…
15㌦こい‼️ -
昨年から買い増ししてholdしてます✊
そろそろ承認来るかなあ
予定は第三四半期! -
同意です。今回はdrugに問題があったわけではないですし、11/8のearning callあたりで$5まで戻ってほしいです。
アルツハイマーSAVAと癌CRDFがマイナスです。
バイオはほぼ投機ですが、応援しがいがありますな -
21
欲張ると駄目ですな。
今年はアルツハイマー関連でも
天国と地獄を見たしバイオは
むずかしいですな。
でも23andMEは期待しています。 -
来年までお預けになりましたね。
-
アフターも上げすぎ👁️
-
ちょっと
上げすぎ。
まだ、目立たなくて良いのに。 -
17
QUQUQ 強く買いたい 2021年10月23日 04:04
上げ加速してきた✨🤭
-
16
QUQUQ 強く買いたい 2021年10月23日 02:06
どうみても
知ってる筋が
集めてる感じ🤭 -
そろそろくるかな🥰
-
14
QUQUQ 強く買いたい 2021年10月22日 02:34
静かに。
しかし
確実に🙊 -
13
10/28が回答期日🤭
-
-
We expect MicroStat (Mydcombi) NDA approval and market launch in the U.S. in 4Q21,” the analyst wrote. “The commercial strategy differs from traditional launches as Eyenovia will not hire a sales force; instead, they will maintain ~10 key account managers to initially focus on the largest practices…. With Eyenovia’s plan to price MicroStat on parity to the current eye drops based on their market research, and with an estimated 80 million dilated eye exams and ~4 million surgeries requiring dilation performed each year, we believe it could represent a significant market opportunity for MicroStat.”
Kaplan gives EYEN shares a Buy rating, along with a $19 price target that implies an impressive upside of 288% in the 12 months ahead. (To watch Kaplan’s track record,
This stock has slipped under the radar to a degree, and has only 2 recent reviews. But both are positive, making for a Moderate Buy consensus view. Eyenovia shares are priced at $4.90 and have an average target of $15.50, giving the stock a 216% upside potential.
🤭目立たず。良い感じ🤭 -
10
QUQUQ 強く買いたい 2021年10月6日 23:46
集めてる感じ🤭🏖️
-
9
QUQUQ 強く買いたい 2021年10月6日 01:43
良い感じ🤭
💛💙💚❤ -
8
QUQUQ 強く買いたい 2021年10月5日 08:30
The company has two drug candidates in advanced development. MicroLine, under investigation as a treatment for presbyopia - a gradual loss of the eye’s ability to focus on nearby objects - has successfully completed the Phase 3 VISION-1 study, and a second Phase 3 trial, called VISION-2, is scheduled for initiation by year’s end. Another drug candidate, MicroPine, is a treatment for nearsightedness in children. This drug has completed enrollment for the Phase 3 CHAPERONE study.
But the drug of interest here is MydCombi, a proprietary, first-in-class combination of pupil dilation drugs. MydCombi is intended as an anesthetic-free, microdosing agent for use in ophthalmic eye exams. This is a high-potential niche, as there are tens of millions of office-based eye exams performed annually in the US alone. In addition, an estimated 4 million cataract surgeries annually are likely to use the drug candidate as well.
The FDA is expected to make its decision on Eyenovia’s NDA for MydCombi shortly, with a PDUFA date set for October 28. A positive decision will clear the path for commercialization, targeting the extensive potential patient base.
🤭10/28 楽しみ🍀 -
7
QUQUQ 強く買いたい 2021年9月8日 03:33
明日、高値更新の予感🤭🏖️
-
-
5
QUQUQ 強く買いたい 2021年9月1日 21:06
来るな🤭
凄く気になる🌅
読み込みエラーが発生しました
再読み込み